Condition
Metastatic Hormone Receptor-Positive Breast Carcinoma clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Metastatic Hormone Receptor-Positive Breast Carcinoma clinical trials that are recruiting, in United States. By phase: Phase 1 (2), Phase 2 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 1Country
Newest Metastatic Hormone Receptor-Positive Breast Carcinoma clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Safety of combining pidnarulex (CX-5461) with trastuzumab deruxtecan for HER2-positive, HER2-low/ultralow breast and other HER2-expressing solid tumors | Phase 1 | Boston, Massachusetts and 1 other locations | Recruiting | Aug 22, 2025 |
| STEMVAC vaccine with hormone therapy plus CDK4/6 inhibitor or capecitabine for metastatic HR-positive, HER2-negative breast cancer | Phase 2 | Seattle, Washington | Recruiting | Aug 8, 2025 |
| Using imaging to predict response to abemaciclib in advanced breast cancer | Phase 2 | St Louis, Missouri and 2 other locations | Recruiting | Dec 21, 2023 |
| Personalized vaccine treatment for advanced melanoma, breast cancer, and lung cancer | Phase 1 | Seattle, Washington | Recruiting | Oct 28, 2021 |
All recruiting trials (4)
-
Safety of combining pidnarulex (CX-5461) with trastuzumab deruxtecan for HER2-positive, HER2-low/ultralow breast and other HER2-expressing solid tumors
This trial tests whether adding pidnarulex to trastuzumab deruxtecan is safe and finds the best dose for adults with HER2-positive, HER2-low/ultralow, or other HER2-expressing advanced or metastatic breast and solid tumors.
-
STEMVAC vaccine with hormone therapy plus CDK4/6 inhibitor or capecitabine for metastatic HR-positive, HER2-negative breast cancer
This trial tests whether adding the STEMVAC vaccine to standard hormone therapy with a CDK4/6 drug, or to capecitabine chemotherapy, helps people with metastatic hormone receptor–positive, HER2‑negative breast cancer.
-
Using imaging to predict response to abemaciclib in advanced breast cancer
This study is testing if special imaging can help doctors figure out which patients with advanced breast cancer will respond best to a new treatment combining abemaciclib and hormone therapy.
-
Personalized vaccine treatment for advanced melanoma, breast cancer, and lung cancer
This study is testing a personalized vaccine combined with a treatment called nivolumab to see if it can help people with advanced melanoma, breast cancer, or lung cancer fight their tumors better.
Related topics
Quick answers
How many Metastatic Hormone Receptor-Positive Breast Carcinoma clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in United States. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 2, Phase 2: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.